Antidepressants show upside in economic downturn

Antidepressants are looking to be big-time recession-busters. In spite of the cost of brand-name meds, Eli Lilly's Cymbalta has grown by leaps and bounds during the economic downturn, with second-quarter sales up by 14 percent year-over-year. And antidepressants in general haven't halted their upward trend, posting $9.6 billion in 2008 sales, up from $9.4 billion in 2007, on 164 million scrips, up from 160 million. Report

Suggested Articles

Intercept presented a data analysis that found treatment with Ocaliva led to "early and consistent improvements" in a range of noninvasive tests.

Intent-driven audiences are inspired to make health-improving changes after a positive online experience. Find out what they’re driven to do.

Days before Amarin faces a pivotal FDA vote on its Vascepa expansion, advisors are set to scrutinize the placebo used in its pivotal outcomes trial.